MUFG Securities EMEA plc Buys 9,935 Shares of GE HealthCare Technologies Inc. $GEHC

MUFG Securities EMEA plc raised its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 113.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,674 shares of the company’s stock after acquiring an additional 9,935 shares during the quarter. MUFG Securities EMEA plc’s holdings in GE HealthCare Technologies were worth $1,532,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Laurel Wealth Advisors LLC acquired a new stake in GE HealthCare Technologies in the fourth quarter valued at $26,000. Optima Capital LLC bought a new stake in shares of GE HealthCare Technologies in the 4th quarter valued at about $27,000. Godfrey Financial Associates Inc. bought a new stake in shares of GE HealthCare Technologies in the 4th quarter valued at about $27,000. Montag A & Associates Inc. raised its holdings in shares of GE HealthCare Technologies by 105.4% in the 4th quarter. Montag A & Associates Inc. now owns 341 shares of the company’s stock valued at $28,000 after purchasing an additional 175 shares during the period. Finally, Maseco LLP bought a new stake in shares of GE HealthCare Technologies in the 4th quarter valued at about $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Buying and Selling

In other news, Director Kevin Lobo bought 10,000 shares of the firm’s stock in a transaction dated Friday, May 22nd. The shares were bought at an average price of $64.18 per share, with a total value of $641,800.00. Following the completion of the transaction, the director owned 14,363 shares of the company’s stock, valued at $921,817.34. This trade represents a 229.20% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO James Saccaro bought 3,310 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was purchased at an average cost of $60.60 per share, for a total transaction of $200,586.00. Following the transaction, the chief financial officer directly owned 87,471 shares of the company’s stock, valued at $5,300,742.60. The trade was a 3.93% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 21,847 shares of company stock valued at $1,361,355 in the last ninety days. 0.36% of the stock is currently owned by company insiders.

GE HealthCare Technologies Price Performance

GE HealthCare Technologies stock opened at $61.99 on Wednesday. GE HealthCare Technologies Inc. has a 12 month low of $58.75 and a 12 month high of $89.77. The stock’s 50 day moving average is $67.53 and its 200-day moving average is $75.81. The company has a current ratio of 1.22, a quick ratio of 0.95 and a debt-to-equity ratio of 0.95. The company has a market capitalization of $28.20 billion, a price-to-earnings ratio of 14.83, a PEG ratio of 1.41 and a beta of 0.74.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its earnings results on Wednesday, April 29th. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.07 by ($0.08). GE HealthCare Technologies had a net margin of 9.10% and a return on equity of 20.46%. The firm had revenue of $5.13 billion during the quarter, compared to analyst estimates of $5.04 billion. During the same period in the previous year, the company posted $1.01 EPS. GE HealthCare Technologies’s revenue for the quarter was up 7.4% compared to the same quarter last year. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. Equities research analysts expect that GE HealthCare Technologies Inc. will post 4.89 EPS for the current year.

Analyst Upgrades and Downgrades

GEHC has been the topic of several research analyst reports. Weiss Ratings lowered GE HealthCare Technologies from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 15th. Jefferies Financial Group dropped their price objective on GE HealthCare Technologies from $105.00 to $90.00 in a research note on Thursday, April 30th. BNP Paribas Exane dropped their price objective on GE HealthCare Technologies from $95.00 to $88.00 in a research note on Friday, May 1st. UBS Group upgraded GE HealthCare Technologies from a “sell” rating to a “neutral” rating and dropped their price objective for the company from $75.00 to $69.00 in a research note on Thursday, May 21st. Finally, Argus dropped their price objective on GE HealthCare Technologies from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Nine analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, GE HealthCare Technologies currently has an average rating of “Moderate Buy” and an average target price of $80.21.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.